TARIS Biomedical Inks $18.3M Series B
Lexington, Mass.-based TARIS Biomedical, which is developing therapies to treat bladder disease, has raised $18.3 million in Series B financing. New investors Third Rock Ventures led the round, which included participation from existing shareholders Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners. The company’s prior bridge financing was also converted into equity in connection with the financing round. Third Rock’s Cary Pfeffer will join the TARIS board.
13 April 2011•3 mins read
